Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-Bor-Dex vs Cy-Bor-Dex in Newly Diagnosed Multiple Myeloma With LCCN
NCT07085728Phase 2Recruiting
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Mar 2026
- Primary completion
- Jan 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Darzalex Faspro in multiple myeloma (MM) and light chain cast nephropathy (LCCN) (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Renal Response Rate at 4 months. Started Mar 2026; status: recruiting.
02
Drugs
Darzalex Faspro
03
Conditions
multiple myeloma (MM)light chain cast nephropathy (LCCN)
Beyond the preview
Go deeper on NCT07085728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085728.